Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Dexcom ( (DXCM) ) has provided an announcement.
On September 14, 2025, Dexcom announced that CEO and Chairman Kevin R. Sayer took a temporary medical leave of absence. Jacob S. Leach, the company’s President and COO, was appointed interim principal executive officer, while Mark Foletta was named interim chairman of the board. Both appointees will not receive additional compensation for their interim roles.
The most recent analyst rating on (DXCM) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Dexcom stock, see the DXCM Stock Forecast page.
Spark’s Take on DXCM Stock
According to Spark, TipRanks’ AI Analyst, DXCM is a Outperform.
Dexcom’s overall stock score reflects strong financial performance and positive earnings call insights, offset by a high valuation and bearish technical indicators. The company’s strategic initiatives and innovation support a positive outlook, but the current market sentiment and valuation present challenges.
To see Spark’s full report on DXCM stock, click here.
More about Dexcom
Dexcom operates in the medical technology industry, specializing in continuous glucose monitoring systems for diabetes management.
Average Trading Volume: 3,906,309
Technical Sentiment Signal: Sell
Current Market Cap: $29.64B
Find detailed analytics on DXCM stock on TipRanks’ Stock Analysis page.